1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Quantum Genomics
  6. Summary
    ALQGC   FR0011648971

QUANTUM GENOMICS

(ALQGC)
  Report
Real-time Euronext Paris  -  11:35 2022-08-11 am EDT
2.866 EUR   +7.26%
06/27Quantum Genomics announces the appointment of its new Scientific Advisory Board
AQ
06/27Quantum Genomics Announces the Appointment of Its New Scientific Advisory Board
CI
06/27QUANTUM GENOMICS : Quantum Genomics announces the appointment of its new Scientific Advisory Board
AN
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
08/05/2022 08/08/2022 08/09/2022 08/10/2022 08/11/2022 Date
2.61(c) 2.652(c) 2.618(c) 2.672(c) 2.866(c) Last
108 622 169 507 85 148 100 683 246 156 Volume
+2.84% +1.61% -1.28% +2.06% +7.26% Change
More quotes
Estimated financial data (e)
Sales 2022 15,6 M 16,1 M 16,1 M
Net income 2022 -5,86 M -6,05 M -6,05 M
Net cash position 2022 20,2 M 20,9 M 20,9 M
P/E ratio 2022 -21,7x
Yield 2022 -
Sales 2023 21,4 M 22,1 M 22,1 M
Net income 2023 3,26 M 3,37 M 3,37 M
Net cash position 2023 26,6 M 27,5 M 27,5 M
P/E ratio 2023 -24,3x
Yield 2023 -
Capitalization 99,2 M 102 M 102 M
EV / Sales 2022 5,06x
EV / Sales 2023 3,39x
Nbr of Employees 7
Free-Float 87,8%
More Financials
Company
Quantum Genomics is a biotechnology company that specializes in the research and development of drugs for the treatment of cardiovascular diseases such as high blood pressure and heart failure. All sales are abroad. 
More about the company
Ratings of Quantum Genomics
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about QUANTUM GENOMICS
06/27Quantum Genomics announces the appointment of its new Scientific Advisory Board
AQ
06/27Quantum Genomics Announces the Appointment of Its New Scientific Advisory Board
CI
06/27QUANTUM GENOMICS : Quantum Genomics announces the appointment of its new Scientific Adviso..
AN
06/27QUANTUM GENOMICS : Nomination
CO
06/13QUANTUM GENOMICS : Universal Registration Document 2021
PU
05/09QUANTUM GENOMICS : Quantum Genomics Announces the End of Patient Recruitment for its Phase..
AN
05/09Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Stu..
AQ
05/09Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Stu..
CI
05/04QUANTUM GENOMICS : Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory ..
AN
05/04Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs
AQ
05/04Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs
CI
05/04QUANTUM GENOMICS : Nomination
CO
05/02QUANTUM GENOMICS : Publication of the Universal Registration Document
PU
05/02QUANTUM GENOMICS : Publication of the Universal Registration Document
AN
04/29QUANTUM GENOMICS : Report
CO
More news
News in other languages on QUANTUM GENOMICS
07/27PENNY STOCKS : Le bilan estival
07/04QUANTUM GENOMICS : Bilan au 30 juin 2022 du contrat de liquidité contracté avec la Société..
06/28Ça va mieux, mais c'est pas encore tout fait ça
06/28EN DIRECT DES MARCHES : TotalEnergies, BofA, Vinci, Eiffage, Volkswagen, JetBlue, Nike, Si..
06/27Quantum Genomics annonce la nomination de son nouveau conseil consultatif scientifique
More news
Chart QUANTUM GENOMICS
Duration : Period :
Quantum Genomics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QUANTUM GENOMICS
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2,87 €
Average target price 12,75 €
Spread / Average Target 345%
EPS Revisions
Managers and Directors
Jean-Philippe Milon Chief Executive Officer & Director
Benoît Gueugnon Chief Financial Officer
Lionel Ségard Chairman
Fabrice Balavoine Vice President-Research & Development
Bruno Besse Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
QUANTUM GENOMICS-37.66%96
MODERNA, INC.-31.38%68 174
LONZA GROUP AG-25.18%44 940
IQVIA HOLDINGS INC.-15.05%44 704
SEAGEN INC.13.62%32 396
ALNYLAM PHARMACEUTICALS, INC.36.81%27 846